Collaborators believe that quantitative detection of HPV viral load is indicative of disease risk.
Cepheid will exclusively license Quantovir’s HPV patent portfolio to develop a diagnostic for cervical cancer. Quantovir has reportedly demonstrated that a molecular test measuring the viral load of HPV DNA present in cervical specimens can be used to predict a woman’s risk of developing cervical cancer.
Cepheid plans to develop a quantitative measurement of high-risk HPV types for the GeneXpert® System. The test is expected to provide accurate PCR results in minutes rather than days in a variety of clinical settings, according to John L. Bishop, CEO of Cepheid.
